second-line treatment strategies for patients with relapsed dlbcl
Published 18 hours ago • 41 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
1:02
the changing standard of care in dlbcl
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
2:43
treatment sequencing options for recurrent cll
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
0:55
the role of clinical trials in improving treatment options for scd
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:36
selecting the best treatment option in cll
-
1:21
the current treatment landscape for scd
-
3:09
treatment strategies for chl patients after auto-hsct
-
1:00
using molecular features to determine appropriate treatment strategies for patients with cll
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
0:56
the current treatment landscape in cll
-
1:55
factors to consider when choosing a treatment option for patients with cll
-
1:18
involving the patient in treatment decisions for cll
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
0:42
targeted therapies for dlbcl treatment